Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Arrowhead Pharmaceuticals, Inc.

SG&A Expenses: HUTCHMED vs. Arrowhead Pharmaceuticals

__timestampArrowhead Pharmaceuticals, Inc.HUTCHMED (China) Limited
Wednesday, January 1, 20142441953626684000
Thursday, January 1, 20153471808929829000
Friday, January 1, 20164099820939578000
Sunday, January 1, 20173202288043277000
Monday, January 1, 20181911005148645000
Tuesday, January 1, 20192655625752934000
Wednesday, January 1, 20205227589061349000
Friday, January 1, 202180981000127125000
Saturday, January 1, 2022124431000136106000
Sunday, January 1, 202390932000133175999
Monday, January 1, 202498761000
Loading chart...

Igniting the spark of knowledge

A Comparative Analysis of SG&A Expenses: HUTCHMED vs. Arrowhead Pharmaceuticals

In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: HUTCHMED (China) Limited and Arrowhead Pharmaceuticals, Inc., from 2014 to 2023. Over this period, HUTCHMED consistently outpaced Arrowhead in SG&A spending, peaking in 2022 with a 10% higher expenditure. Notably, HUTCHMED's expenses surged by approximately 410% from 2014 to 2022, reflecting its aggressive expansion strategy. In contrast, Arrowhead's SG&A expenses grew by about 410% over the same period, indicating a more measured approach. The data for 2024 is incomplete, highlighting the need for ongoing analysis. This comparison underscores the strategic financial decisions shaping the future of these pharmaceutical giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025